Naoki Takahashi1, Kazuko Omodaka1, Tsutomu Kikawa2, Masahiro Akiba2, Toru Nakazawa1,3,4. 1. Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan. 2. Topcon Corporation, Tokyo, Japan. 3. Department of Retinal Disease Control, Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan. 4. Department of Advanced Ophthalmic Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Abstract
Purpose: Maintaining visual acuity in glaucoma patients is an important part of preventing the deterioration of quality of vision. We identified specific areas of the papillomacular bundle (PMB) that were strongly associated with visual acuity, based on en-face images derived from optical coherence topography (OCT) wide scans. Methods: The study recruited 23 eyes of 21 glaucoma patients (age: 61.3 ± 13.0 years, M: F = 9:12, Humphrey field analyzer-measured mean deviation: -19.9 ± 6.5 dB) with good best-corrected visual acuity (20/20 or more) and a remaining PMB with a maximum width no more than half that of the vertical disc diameter. En-face images were derived from 12 × 9 mm wide-scan images made with DRI-OCT (Triton, Topcon). Averaged en-face images were created by identifying the disc center and fovea line (DFL) and aligning it between images. We then measured the frequency of remaining PMB at 10 µm intervals along a vertical line intersecting the DFL at its midpoint. Finally, we used a logistic analysis in a much larger group of patients to identify cases of glaucoma with low BCVA (<20/20). Results: In the averaged en-face image, the residual PMB area appeared as a high-intensity region above the DFL. Analysis showed that residual PMB was most common in an area 830-870 µm above the DFL. The correlation coefficient of residual PMB in this area to BCVA was -0.57 (p < .01), and among OCT parameters in this residual PMB area, the AUC to identify decreased BCVA was highest for ganglion cell complex thickness (0.85, p < .01), with a cutoff of 87.5 µm.Conclusions: This study identified specific areas of the PMB that were associated with BCVA in wide-scan, en-face OCT images from glaucoma patients. This suggests that it may be possible to identify visual impairment during glaucoma treatment by measuring this area.
Purpose: Maintaining visual acuity in glaucoma patients is an important part of preventing the deterioration of quality of vision. We identified specific areas of the papillomacular bundle (PMB) that were strongly associated with visual acuity, based on en-face images derived from optical coherence topography (OCT) wide scans. Methods: The study recruited 23 eyes of 21 glaucoma patients (age: 61.3 ± 13.0 years, M: F = 9:12, Humphrey field analyzer-measured mean deviation: -19.9 ± 6.5 dB) with good best-corrected visual acuity (20/20 or more) and a remaining PMB with a maximum width no more than half that of the vertical disc diameter. En-face images were derived from 12 × 9 mm wide-scan images made with DRI-OCT (Triton, Topcon). Averaged en-face images were created by identifying the disc center and fovea line (DFL) and aligning it between images. We then measured the frequency of remaining PMB at 10 µm intervals along a vertical line intersecting the DFL at its midpoint. Finally, we used a logistic analysis in a much larger group of patients to identify cases of glaucoma with low BCVA (<20/20). Results: In the averaged en-face image, the residual PMB area appeared as a high-intensity region above the DFL. Analysis showed that residual PMB was most common in an area 830-870 µm above the DFL. The correlation coefficient of residual PMB in this area to BCVA was -0.57 (p < .01), and among OCT parameters in this residual PMB area, the AUC to identify decreased BCVA was highest for ganglion cell complex thickness (0.85, p < .01), with a cutoff of 87.5 µm.Conclusions: This study identified specific areas of the PMB that were associated with BCVA in wide-scan, en-face OCT images from glaucoma patients. This suggests that it may be possible to identify visual impairment during glaucoma treatment by measuring this area.